Treace Medical Concepts, Inc. is a medical technology company. It is advancing the standard of care for the surgical management of bunion and related midfoot deformities. It has patented the Lapiplasty 3D Bunion Correction System a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. It has Adductoplasty Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, the SpeedMTP Rapid Compression Implant for addressing bunions through big toe joint fusions, and two systems for minimally invasive osteotomy surgeries: the Nanoplasty 3D Minimally Invasive Bunion Correction System and the Percuplasty Percutaneous 3D Bunion Correction System. It sells its products to physicians, surgeons, ambulatory surgery centers, hospitals, and stocking distributors.
BörsenkürzelTMCI
Name des UnternehmensTreace Medical Concepts Inc
IPO-datumApr 23, 2021
CEOTreace (John T)
Anzahl der mitarbeiter477
WertpapierartOrdinary Share
GeschäftsjahresendeApr 23
Addresse100 Palmetto Park Place
StadtPONTE VEDRA
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl32081
Telefon19043735940
Websitehttps://www.treace.com/
BörsenkürzelTMCI
IPO-datumApr 23, 2021
CEOTreace (John T)
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten